Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?

Show simple item record

dc.contributor.author O'Driscoll, Caitríona M.
dc.contributor.author Bernkop-Schnürch, Andreas
dc.contributor.author Friedl, Julian D.
dc.contributor.author Préat, Véronique
dc.contributor.author Jannin, Vincent
dc.date.accessioned 2019-11-19T12:07:33Z
dc.date.available 2019-11-19T12:07:33Z
dc.date.issued 2019-05-15
dc.identifier.citation O'Driscoll, C.M., Bernkop-Schnürch, A., Friedl, J.D., Préat, V. and Jannin, V., 2019. Oral delivery of non-viral nucleic acid-based therapeutics-do we have the guts for this?. European Journal of Pharmaceutical Sciences, 133, (14pp). DOI:10.1016/j.ejps.2019.03.027 en
dc.identifier.volume 133 en
dc.identifier.startpage 190 en
dc.identifier.endpage 204 en
dc.identifier.issn 0928-0987
dc.identifier.uri http://hdl.handle.net/10468/9083
dc.identifier.doi 10.1016/j.ejps.2019.03.027 en
dc.description.abstract Gene therapy with RNA and pDNA-based drugs is limited by poor enzymatic stability and poor cellular permeation. The delivery of nucleic acids, in particular by the oral route, remains a major hurdle. This review will focus on the barriers to the oral delivery of nucleic acids and the strategies, in particular formulation strategies, which have been developed to overcome these barriers. Due to their very low oral bioavailability, the most obvious and most investigated biomedical applications for their oral delivery are related to the local treatment of inflammatory bowel diseases and colorectal cancers. Preclinical data but not yet clinical studies support the potential use of the oral route for the local delivery of formulated nucleic acid-based drugs. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier B.V. en
dc.relation.uri https://www.sciencedirect.com/science/article/pii/S0928098719301368?via%3Dihub
dc.rights © 2019 The Authors. Published by Elsevier B.V. en
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Nucleic acid en
dc.subject Oral delivery en
dc.subject RNA en
dc.subject pDNA en
dc.subject Nanoparticles en
dc.subject Lipid-based particles en
dc.subject Inflammatory bowel disease en
dc.title Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this? en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Catriona O'Driscoll, School of Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email: caitriona.odriscoll@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder European Cooperation in Science and Technology en
dc.description.status Peer reviewed en
dc.identifier.journaltitle European Journal of Pharmaceutical Sciences en
dc.internal.IRISemailaddress caitriona.odriscoll@ucc.ie en
dc.identifier.eissn 1879-0720


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors. Published by Elsevier B.V. Except where otherwise noted, this item's license is described as © 2019 The Authors. Published by Elsevier B.V.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement